Ghent University Hospital
Internal medicine and pediatrics
Leslie Naesens is a medical doctor at the Ghent University Hospital, specialized in internal medicine with a focus on immunology and primary immunodeficiency diseases. In 2018, he started his PhD at the Primary Immunodeficiency Research Lab of Prof. Filomeen Haerynck. His doctoral research centers around innate immune disorders for which he pursued additional education in "Innate Immunity and Infectious Diseases" at the Institut Pasteur in Paris. He is a beneficiary of a FWO Flanders fundamental research grant. In 2022, he was awarded with a Horlait-Dapsens scholarship and completed a fellowship in Microbiology and Innate Immunity at the Cleveland Clinic - Florida Research and Innovation Center. His research work involves studies on complement deficiencies, autoinflammatory disorders and innate viral sensing mechanisms.

Presenter of 1 Presentation

GTF3A DEFICIENCY IN HUMANS PREDISPOSES TO HERPES SIMPLEX ENCEPHALITIS BY ABROGATING TRANSCRIPTION OF THE HOST-DERIVED RIG-I LIGAND RNA5SP141

Session Type
Oral Communications
Date
Fri, 14.10.2022
Session Time
17:35 - 18:35
Room
Session Hall 01
Lecture Time
18:27 - 18:35

Abstract

Background and Aims

Monogenic defects in type I interferon (IFN-I) signaling components have been identified in patients with herpes simplex encephalitis (HSE), emphasizing inborn errors of immunity underlying pathogenesis. In vitro studies demonstrate that the cytoplasmic RNA sensor RIG-I, which is well known to restrict RNA viruses, also critically contributes to the innate immune responses to DNA viruses including HSV-1.

Methods

We identified compound heterozygous mutations in the gene GTF3A in a family afflicted by HSE in early childhood. We studied primary patient cells as well as several CRISPR/Cas9-edited GTF3A mutant cells.

Results

GTF3A encodes for the transcription factor TFIIIA, which is part of the Pol III complex. We confirmed that the patient TFIIIA mutants have an impaired promoter-binding ability. We tested HSV-1 replication in the patient fibroblasts and GTF3A mutant cells and observed enhanced viral replication. To understand the underlying mechanism, we took an unbiased approach and searched for novel transcriptional targets of TFIIIA by ChIP-seq analysis and identified the pseudogene RNA5SP141, previously described as a RIG-I agonist. We found that RNA5SP141 is upregulated following HSV-1 infection and that this induction is abrogated in primary patient cells, in GTF3A gene-edited mutant cells, and upon targeted knockdown using siRNA. Finally, we explored the downstream effects of impaired RNA5SP141 expression on anti-herpesviral immunity and found abrogated RIG-I activation and markedly diminished induction of antiviral genes during HSV-1 infection.

Conclusions

Our work unveils a novel role for TFIIIA, acting as a moonlighting protein that regulates innate immune responses to HSV-1 by transcriptional regulation of the host-derived RNA5SP141 RIG-I ligand.

Hide